A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO EVALUATE PALATABILITY AND RELATIVE BIOAVAILABILITY OF TWO PEDIATRIC MICROSPHERE FORMULATIONS OF CRIZOTINIB IN HEALTHY PARTICIPANTS
Latest Information Update: 17 Aug 2021
At a glance
- Drugs Crizotinib (Primary) ; Crizotinib; Esomeprazole
- Indications Anaplastic large cell lymphoma; Bladder cancer; Glioblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 13 Nov 2019 Status changed from recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 8 Oct 2019 to 16 Oct 2019.
- 30 Jul 2019 Planned primary completion date changed from 8 Oct 2019 to 16 Oct 2019.